The recent confiscation of fake Mounjaro injections in Gurugram, valued at approximately Rs 70 lakh, highlights the troubling rise of counterfeit products in India’s expanding market for GLP-1-based therapies. Authorities in Haryana have initiated a crackdown that reveals a concerning trend: as the demand for effective diabetes and weight-loss medications grows, so does the emergence of substandard alternatives.

Mounjaro, produced by the American pharmaceutical company Eli Lilly, contains tirzepatide and is part of a new class of GLP-1 receptor agonists, which are commonly prescribed for managing type II diabetes and are increasingly used for obesity treatment. The drug was introduced to the Indian market in March of last year initially in vial form, followed by a more user-friendly KwikPen configuration.

The significant uptake of Mounjaro is reflected in its sales figures, with the product reportedly generating Rs 114 crore in sales last month, making it the highest-grossing drug in the country, as per data from Pharmarack. Its sales performance has maintained a leading position since it became the top-selling drug by value in October.

Challenges in Identifying Counterfeit Injections

The dramatic surge in demand for GLP-1 therapies in India can be attributed to rising cases of diabetes and an increasing inclination for off-label weight loss solutions. Mounjaro’s weekly treatment expenses range from Rs 3,500 for the lowest dosage to nearly Rs 6,875 for the highest, which contributes to its appeal as a target for counterfeiters.

Authorities are still assessing whether the seized injections are classified as “not of standard quality” (NSQ) or as outright counterfeit. Initial findings suggest an intentional attempt to replicate the appearance of the genuine product, as counterfeit drugs in India typically fall into two categories: NSQ drugs that do not meet quality standards and spurious drugs that are manufactured to mimic genuine items.

Identifying counterfeit drugs poses a significant challenge. Preliminary evaluations of the seized Mounjaro revealed various inconsistencies in packaging, such as irregular font sizes and label deviations that may easily go unnoticed by consumers. However, experts advise that merely checking for visual inaccuracies is insufficient for ensuring product integrity.

Systemic Vulnerabilities in Pharmaceutical Distribution

The incident in Gurugram sheds light on systemic weaknesses within India’s pharmaceutical distribution framework. Despite improvements in regulatory oversight, gaps remain, particularly in urban areas where informal distribution networks flourish. Furthermore, the rise of online sales through social media platforms complicates monitoring efforts, as these channels often bypass traditional pharmacy regulations.

Experts assert that consumer awareness must be prioritised alongside regulatory measures. Basic verification steps—such as checking batch numbers, scrutinising packaging for typos or blurred logos, and ensuring purchases are made through licensed pharmacies—can significantly mitigate risks associated with counterfeit products. Unusually high discounts on expensive biologics may also serve as warning signs.

According to Dr Rajeev Kovil, a consultant in diabetes management based in Mumbai, the efficacy of GLP-1 therapies relies on a well-structured system involving controlled production, cold chain logistics, and monitored clinical application. Any disruption within this ecosystem can lead to unreliable treatment outcomes, making it imperative for all components of the system to function cohesively.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share